Cargando…
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
Background: Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is the third most common acute cardiovascular disease and represents an important burden for patients and payers. Objective: The aim was to estimate the cost-effectiveness of edoxaban, a...
Autores principales: | Clay, Emilie, Jamotte, Aurélien, Verhamme, Peter, Cohen, Alexander T., Van Hout, Ben. A., Gumbs, Pearl. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052426/ https://www.ncbi.nlm.nih.gov/pubmed/30034645 http://dx.doi.org/10.1080/20016689.2018.1495974 |
Ejemplares similares
-
Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017) -
Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016) -
Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013) -
Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
por: Hara, Nobuhiro, et al.
Publicado: (2017) -
Risk impact of edoxaban in the management of stroke and venous thromboembolism
por: Hurst, Katherine V, et al.
Publicado: (2016)